# Organic & Biomolecular Chemistry



View Article Online

## PAPER



Cite this: DOI: 10.1039/c4ob02109f

## An improved procedure to prepare 3-methyl-4-nitroalkylenethylisoxazoles and their reaction under catalytic enantioselective Michael addition with nitromethane<sup>+</sup>

Maria Moccia,\* Robert J. Wells and Mauro. F. A. Adamo\*

Received 3rd October 2014, Accepted 2nd December 2014 DOI: 10.1039/c4ob02109f Herein, we describe a short synthesis of 3-methyl-4-nitro-5-alkylethenyl isoxazoles and their reactivity as Michael acceptors. The title compounds reacted with nitromethane under phase-transfer catalysis to provide highly enantioenriched adducts (up to 93% ee) which were then converted to the corresponding  $\gamma$ -nitroacids.

www.rsc.org/obc

### Introduction

The isoxazole nucleus is an important pharmacophore in medicinal chemistry, due to its isosterism with an ester.<sup>1</sup> In addition isoxazoles could be employed as precursors to notable organic compounds such as 1,3-dicarbonyls,<sup>2</sup> hydroxy-ketones,<sup>3</sup> azirines,<sup>4</sup> enamines and  $\beta$ -hydroxynitriles.<sup>5</sup> In the recent past, we have developed several synthetic routes starting from aromatic styrylisoxazoles 2 (Scheme 1).<sup>6–11</sup> In compounds 2, the 4-nitroisoxazole core activates the exocyclic alkene to react with soft nucleophiles. The 4-nitroisoxazole could be converted to a carboxylate *via* basic,<sup>12</sup> oxidative<sup>13</sup> and acidic<sup>14</sup> procedures which justified the definition of compounds 2 as a synthetic equivalent to cinnamates 1.

Following our reports, the synthetic relevance of compounds **2** has been recognized by other groups: Shibata reported the synthesis of trifluoromethylisoxazolines *via* addition of  $CF_3^-$  nucleophiles to compounds **2**;<sup>15</sup> Yuan



Scheme 1 Retrosynthetic analysis of 3-methyl-4-nitro-5-styrilisoxazoles 2.



Scheme 2 Condensation of 3 and aliphatic aldehydes in [bmlm]-OH.

reported a highly enantioselective thiolate addition to compounds **2** catalysed by bifunctional organocatalysts;<sup>14</sup> Rui Wang reported a highly enantioselective addition of unsaturated lactams to **2** catalysed by quinine-based thioureas.<sup>16</sup>

The preparation of aromatic compounds 2 proceeded *via* condensation of commercially available 3,5-dimethyl-4-nitro-isoxazole **3** and aromatic or heteroaromatic aldehydes **4**.<sup>17</sup>

However, the same procedure failed when aliphatic aldehydes were employed.<sup>6,18</sup> Considering the growing interest in reagents 2, we have recently reported a method to prepare aliphatic 5-ethenyl-4-nitroisoxazoles.<sup>18</sup> The synthesis involved four steps and allowed obtaining compounds 7 (Scheme 2) in high yields and exclusively as *E* stereoisomers.<sup>18</sup>

#### Results and discussion

With the intention of streamlining the preparation of compounds 7, we reconsidered the condensation of commercially available 3 and aliphatic aldehydes 5a–i under a new set of hitherto unexplored conditions. This study identified a twostep procedure that allowed condensation of commercially available 3,5-dimethyl-4-nitroisoxazole 3 and aliphatic aldehydes 5a–i to alkylethenylisoxazole 7a–i (Scheme 2). The

Centre for Synthesis and Chemical Biology (CSCB), Department of Pharmaceutical and Medicinal Chemistry, Royal College of Surgeons in Ireland, 123 St. Stephen's Green, Dublin 2, Ireland. E-mail: madamo@rcsi.ie, mariamoccia@rcsi.ie; Fax: (+353) 1 4022168

<sup>†</sup>Electronic supplementary information (ESI) available: Experimental procedures, characterization data, and spectra of new compounds. See DOI: 10.1039/c4ob02109f

synthetic relevance of compounds 7a-i was then demonstrated by their reaction with nitromethane under phase transfer catalysis (PTC).<sup>19</sup> This reaction provided pharmaceutically relevant adducts 9a-i in high enantiomeric excesses (Table 4).

During our studies on the preparation of compounds 7, Reddy reported a fast preparation of 2 (vields of 85-92% in 10-15 minutes) that occurred at room temperature. The new procedure involved the use of 1-butyl-3-methylimidazolium hydroxide [bmIm]-OH as the media.<sup>20</sup> The fast rates described by Reddy prompted us to react 3 and 5d (Scheme 2) in [bmIm]-OH.

Hence, equimolar amounts of 3,5-dimethyl-4-nitroisoxazole 3 and isovaleraldehyde 5d were taken in IL [bmIm]-OH and the reaction mixture was stirred at room temperature for 1 h. This reaction provided 20% of compound 7d and 32% of alcohol 6d. Increase of temperature, reaction time or reactant concentration did not prove useful and 7d was obtained in yields not greater than 20-25%.

The unprecedented reaction of 3 and aliphatic 5d in IL [bmIm]-OH was explained considering quantitative formation of deprotonated 3 which is very stable in a polar solvent. The high concentration of deprotonated 3 was responsible for the generation of compounds 6d and 7d. In order to prove this, we have designed a new protocol in which compound 3 was first reacted with 1 equiv. of NaOH in a mixture of 9:1 of ethanolwater and then the resulting metallated-3 quenched with isovaleraldehyde 5d.

This new protocol provided about 50% of compounds 6d and 7d in 1:1 ratio, proving therefore that the amount of ionized 3 was crucial to ensure progress of the desired aldol reaction.

Further improvements were logically achieved by (a) reduction of NaOH base to 0.2 equiv., to decrease aldehyde self-condensation; (b) replacement of ethanol with methanol to increase the amount of isoxazole 3 in solution; (c) addition

of THF as a co-solvent to favor the formation of a homogeneous phase.

Delightfully, under this set of optimized conditions, the reaction of 3 and aldehydes 5a-i proceeded to completion and alcohols 6a-i were obtained in high isolated yields (Table 1).

Compounds 6a-i were then treated with a small excess of methane sulfonyl chloride (1.2 equiv.) and an excess of triethylamine (2 equiv.), providing the corresponding alkenes 7a-i in good to excellent yields (Table 2). Significantly, only the *E*-alkene was observed.

This two steps procedure was run under a milder set of conditions (NaOH in H<sub>2</sub>O/MeOH) compared to those previously reported (LDA in THF)<sup>18</sup> and expanded significantly the scope of alkenes 7 that could be prepared. The reactivity of compounds 7a-i was then tested in the Michael reaction with nitromethane. We initially treated a solution of 7d in toluene (0.1 M) with nitromethane (5 equiv.), solid K<sub>2</sub>CO<sub>3</sub> (5 equiv.), a suitable combination of bases and solvents already reported by us,<sup>6</sup> with a range of *cinchonidine*-derived phase transfer catalysts (Table 3).

The use of catalysts 8 and 8.2 at room temperature provided compound 9d in 86% ee (Table 3, entries 1 and 5). The reaction carried out at lower temperature (-30 °C) afforded 9d in a decreased enantiomeric excess (Table 3, entry 3). The use of commercially available catalyst 8.3 provided the desired product 9d in a lower 74% at 0 °C (Table 3, entry 7). Similarly, catalysts 8.4 and 8.5 gave 9d in reduced enantioselectivity (Table 3, entries 8 and 9). Final optimisation involved the use of 10 mol% of catalyst and diluting the reaction from 0.1 M to 0.03 M, which enhanced the ee. Hence, the optimised set of conditions required the use of 10 mol% of catalyst 8 at 0 °C, solid K<sub>2</sub>CO<sub>3</sub> as the base, a concentration of reagents of 0.03 M (Table 3, entry 4). Importantly, the use of pseudoenantiomeric catalysts allowed obtaining ent-9d in similarly high ee (Table 3, entries 2 and 6).

The scope of the reaction was shown by reacting alkylethenylisoxazoles 7a-i with nitromethane under the catalysis of 8

Table 1	Synthesis of	of hydroxyl	isoxazoles

NO

II C

$\begin{array}{c} H_{3}C\\ H_{2}\\ H_{2}\\ H_{2}\\ H_{2}\\ O/MeOH/THF \end{array} \xrightarrow{OH} \xrightarrow{OH} \xrightarrow{O-1}_{NO_{2}}$					
Entry <sup>a</sup>	Ald.	R group	<i>T</i> [h]	Prod.	Yields <sup>b</sup> [%]
1	5a	CH <sub>2</sub> CH <sub>3</sub>	36	6a	90
2	5b	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	36	6b	88
3	5c	$(CH_2)_3CH_3$	36	6c	88
4	5d	$CH_2CH(CH_3)_2$	36	6d	92
5	5e	$(CH_2)_4CH_3$	48	6e	87
6	5f	$(CH_2)_5CH_3$	48	6f	88
7	5g	$(CH_2)_6CH_3$	48	6g	85
8	5ĥ	$(CH_2)_7 CH_3$	60	6ĥ	84
9	5i	$(CH_2)_8CH_3$	60	6i	84

<sup>a</sup> Reaction conditions: 3,5-dimethyl-4-nitroisoxazole 3 (5 mmol), H<sub>2</sub>O/ MeOH/THF, NaOH (0.2 mmol), aldehydes 5a-i (6 mmol), 18 °C. <sup>b</sup> Isolated yields after flash column chromatography.

#### Table 2 Cumblessie of alloweathed issuesales

Table	2 Synthesis of alkenethyl isoxa	Izoles		
$\begin{array}{c} OH \\ R \\ \hline \mathbf{6a-i} \\ NO_2 \end{array} \xrightarrow{MsCl (1.2 eq), Et_3N (2 eq)} \\ \hline CH_2Cl_2, 0^{\circ}C \text{ then } 18^{\circ}C \\ \hline \mathbf{7a-i} \\ NO_2 \end{array}$				
Entry	R	Prod.	Yield <sup>b</sup> [%]	
1	$CH_2CH_3$	7a	98	
2	$CH_2CH_2CH_3$	7 <b>b</b>	96	
3	$(CH_2)_3CH_3$	7c	97	
4	$CH_2CH(CH_3)_2$	7 <b>d</b>	95	
5	$(CH_2)_4CH_3$	7e	96	
6	$(CH_2)_5 CH_3$	7 <b>f</b>	94	
7	$(CH_2)_6CH_3$	7g	90	
8	$(CH_2)_7 CH_3$	$7\bar{h}$	88	
9	$(CH_2)_8CH_3$	7i	88	

<sup>a</sup> Reaction conditions: 6a-i (1 mmol), CH<sub>2</sub>Cl<sub>2</sub> (7mL), MsCl (1.2 mmol), Et<sub>3</sub>N (2 mmol), 0 °C then 18 °C. <sup>b</sup> Isolated yields after flash column chromatography.

Table 3 Representative results of the screening of cinchonidinederived catalysts 8–8.5



Entry <sup>a</sup>	Cat.	Temp [°C]	T[h]	Conv. <sup>b</sup> [%]	ee <sup>c</sup> [%]
1	8	RT	1.5	98	86
2	8	0	3	98	$87(72)^d$
3	8	-30	18	87	82
4	8.1	0	18	98	73
5	8.2	RT	0.25	92	86
6	8.2	0	1.5	92	$86(85)^d$
7	8.3	0	18	98	74
8	8.4	0	48	98	78
9	8.5	0	24	98	53

<sup>*a*</sup> Reaction conditions: alkenethylisoxazole 7d (0.1 mmol), toluene (1.0 mL), cat. 8–8.5 (10 mol%), nitromethane (0.5 mmol),  $K_2CO_3$  (0.5 mmol). <sup>*b*</sup> Conversion was determined by <sup>1</sup>H NMR analysis. <sup>*c*</sup> The enantiomeric excess (ee) of the product was determined by chiral stationary phase HPLC. <sup>*d*</sup> In parentheses the ee of *ent*-9d obtained using the pseudoenantiomeric catalysts 8 and 8.2.

(Table 4). The results collected pointed out: (a) compounds containing either short (7a,7b) or long chains (7h,7i) were equally good substrates and the corresponding compounds 9a,b and 9h,i were obtained in good yields and in up to 93% ee; (b) importantly, it was verified that at least compounds 9a,

Table 4 Enantioselective addition of nitromethane to alkenethenyl-isoxazoles 7a-i under the catalysis of 8

	R 7a-i NO <sub>2</sub>	$CH_3NO_2$ (5 eq) Cat.8 (0.1 eq) $K_2CO_3$ (5 eq.) Toluene 0°C	O <sub>2</sub> N R ( <i>R</i> ) 9 a-i NO <sub>2</sub>	-
Entry <sup>a</sup>	R	Prod.	$\operatorname{Yield}^{b}[\%]$	ee <sup>c</sup> [%]
1	CH <sub>2</sub> CH <sub>3</sub>	<b>9</b> a <sup>d</sup>	91	93
2	CH <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	$\mathbf{9b}^d$	91	87
3	$(CH_2)_3CH_3$	9c	90	88
4	$CH_2CH(CH_3)_2$	$\mathbf{9d}^d$	90	89
5	$(CH_2)_4CH_3$	$\mathbf{9e}^d$	91	88
6	$(CH_2)_5CH_3$	$\mathbf{9f}^d$	90	86
7	$(CH_2)_6CH_3$	9g	99	83
8	$(CH_2)_7 CH_3$	9ĥ	89	87
9	$(CH_2)_8CH_3$	$9i^d$	89	85

<sup>*a*</sup> Reaction condition: styrylisoxazoles **7a-i** (0.2 mmol), toluene (6.7 mL), cat. **8** (0.02 mmol), CH<sub>3</sub>NO<sub>2</sub> (1 mmol), K<sub>2</sub>CO<sub>3</sub> (1 mmol). <sup>*b*</sup> Isolated yields after flash column chromatography. <sup>*c*</sup> The enantiomeric excess (ee) of the product was determined by chiral stationary phase HPLC. <sup>*d*</sup> Reaction performed on a 5.0 mmol scale.

Table 5 Synthesis of aliphatic γ-nitro acids<sup>a</sup>



<sup>a</sup> Reaction conditions: compounds 9 (0.25 mmol), THF (0.5 mL), aqueous NaOH (1.25 mmol), reflux. <sup>b</sup> Isolated yields after flash column chromatography.



Scheme 3 Preparation of enantioenriched (S)-Pregabalin 11.

**c,d,e,f,i** could be obtained in a preparative scale (Table 4) without loss of yield or enantioselectivity. The absolute configuration of compounds **9a–i** obtained was determined to be *R* by comparison of optical rotation and HPLC data of compounds **10d** and *ent-***10d** with published data.<sup>21</sup>

The carboxylic acid functionality was then unveiled from Michael adducts **9a,b,d,e,f,i** (Table 5) which were efficiently converted into the corresponding  $\gamma$ -nitro acids **10a,b,d,e,f,i** in high yields (87%–94%).

This transformation required treatment with 1 M aqueous NaOH in THF. The ee reflected the values of the starting materials thus demonstrating the stereochemical stability of compounds under the conditions adopted.<sup>6</sup> The  $\gamma$ -nitroacids obtained are important intermediates as precursors of  $\gamma$ -amino acids.<sup>5,7,16</sup> This has been demonstrated by reducing  $\gamma$ -nitroacid *ent*-10d to enantioenriched (*S*)-Pregabalin 11 (Scheme 3), using a literature procedure.<sup>22</sup>

#### Conclusions

In conclusion, we have developed a new short synthesis of *E*-alkenylethyl isoxazoles, the aliphatic version of a popular class of Michael acceptors. Similarly to their aromatic analogues **2**, compounds 7 reacted promptly under phase transfer catalysis providing highly enantioenriched nitromethane adducts. This study delivers to the scientific community a novel enantioselective strategy for the synthesis of aliphatic  $\gamma$ -nitroacids and confirms 4-nitro-5-alkethenylisoxazoles as a useful synthon for organic synthesis.

### Notes and references

- D. Xiao, X. Zhu, Y. Yu, N. Shao, J. Wu, K. D. McCormick, P. Dhondi, J. Qin, R. Mazzola, H. Tang, A. Rao, P. Siliphaivanh, H. Qiu, X. Yang, M. Rivelli, C. G. Garlisi, S. Eckel, G. Mukhopadhyay, C. Correll, D. Rindgen, R. Aslanian and A. Palani, *Bioorg. Med. Chem. Lett.*, 2014, 24, 1615.
- 2 A. Barbero and F. J. Pulido, Synthesis, 2004, 401.
- 3 J. W. Bode and E. M. Carreira, Org. Lett., 2001, 3, 1587.
- 4 R. Nesi, D. Giomi and S. Turchi, *J. Org. Chem.*, 1998, 63, 6050.
  5 R. Nesi, S. Turchi and D. Giomi, *J. Org. Chem.*, 1996, 61, 7933.
- 6 A. Baschieri, L. Bernardi, A. Ricci, S. Suresh and M. F. A. Adamo, *Angew. Chem., Int. Ed.*, 2009, **48**, 9342.
- 7 M. F. A. Adamo, E. F. Duffy, D. Donati and P. Sarti-Fantoni, *Tetrahedron*, 2007, **63**, 2684.
- 8 M. F. A. Adamo and V. R. Konda, Org. Lett., 2007, 9, 303.
- 9 F. Fini, M. Nagabelli and M. F. A. Adamo, *Adv. Synth. Catal.*, 2010, **352**, 3163.
- 10 S. Bruschi, M. Moccia and M. F. A. Adamo, *Tetrahedron Lett.*, 2011, **52**, 3602.
- 11 M. F. A. Adamo, D. Donati, E. F. Duffy and P. Sarti-Fantoni, *J. Org. Chem.*, 2005, **70**, 8395.

- 12 M. F. A. Adamo, P. Sarti-Fantoni, S. Chimichi and A. Sandrelli, *Tetrahedron Lett.*, 2010, **51**, 6310.
- C. Del Fiandra, L. Piras, F. Fini, P. Disetti, M. Moccia and M. F. A. Adamo, *Chem. Commun.*, 2012, 48, 4215.
- 14 Q. L. Pei, H. W. Sun, Z. J. Wu, X.-M. Zhang and W. C. Yuan, *J. Org. Chem.*, 2011, **76**, 7849.
- 15 H. Kawai, K. Tachi, E. Tokunaga, M. Shiro and N. Shibata, Angew. Chem., Int. Ed., 2011, 50, 7803.
- 16 J. Zhang, X. Liu, X. Ma and R. Wang, *Chem. Commun.*, 2013, **49**, 9329.
- 17 M. F. A. Adamo, E. F. Duffy, V. R. Konda and F. Murphy, *Heterocycles*, 2007, **71**, 1173.
- 18 R. Wells, M. Moccia and M. F. A. Adamo, *Tetrahedron Lett.*, 2014, 55, 803.
- 19 Asymmetric Phase Transfer Catalysis, ed. K. Maruoka, Wiley-VCH, Weinheim, 2008.
- 20 E. Rajanarendar, S. Raju, A. Siva, S. R. Reddy, K. G. Reddy and M. N. Reddy, *Chem. Pharm. Bull.*, 2010, **58**, 833.
- 21 H. Gotoh, H. Ishikawa and Y. Hayashi, *Org. Lett.*, 2007, **9**(25), 5307.
- F. Berti, F. Felluga, C. Forzato, G. Furlan, P. Nitti, G. Pitacco and E. Valentin, *Tetrahedron: Asymmetry*, 2008, **19**, 945;
  M. F. A. Adamo, *PCT Int. App*, WO 2013076225 A1 20130530, 2013.